This peptide, which is a C-terminal analogue of the complement factor C3a, acts as an agonist to the C3a receptor. It is derived from the fifteen C-terminal residues (6-77) of C3a. In in vitro studies, both C 3a and this peptide have been shown to selectively bind to C3aRs and induce degranulation of C3aR-transfeted RBL-2H3 cells. There was also a rapid, transient and concentration-dependent hypertensive response observed in rats when infused intravenously with C3a and this peptide.
Proteins & Peptides
Peak Area by HPLC ≥95%
1, Proctor LM et al. Intl Immunopharmacol. 9, 800-806 (2009). 2, Ames, R. et al. Immunopharmacol. 38, 87 (1997).